Enterprise Value

3.384B

Cash

901M

Avg Qtr Burn

-44.61M

Short % of Float

8.57%

Insider Ownership

2.14%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

NDA

Submission

Paltusotine (SST2 agonist) Details
Neuroendocrine tumor, Carcinoid syndrome

Phase 3

Initiation

Phase 2

Data readout

Phase 1/2

Data readout

Failed

Discontinued